Among the three programs are mRNA-1608, a candidate against Herpes simplex virus , mRNA-1468, a candidate against varicella-zoster virus to reduce the rate of herpes zoster , and mRNA-4359, a new checkpoint cancer vaccine.
The vaccine candidates, mRNA-1608 and mRNA 1468 are against HSV and VZV respectively, which are latent viruses that remain in the body for life after infection and can lead to life-long medical conditions. Herpes simplex viruses are categorized into two types: HSV-1 infects the mouth, face, and genitals, and HSV-2 primarily infects the genitals. Both viruses establish lifelong latent infections within nearby sensory neurons from which they can reactivate and re-infect the skin. In the U.S.,ages 18 to 49 years are living with HSV-2. Approximately 5 percent of the world population in the 18-to-49-year age range is HSV-2 seropositive.
However, NSCLC frequently goes undetected, remaining asymptomatic until it has progressed to later stages. Approximately, 115,000 people areThe company currently has five vaccine candidates against latent viruses in development, including against cytomegalovirus , Epstein-Barr virus , Human immunodeficiency virus , HSV and VZV.
🙄
Brilliant science there. Well done.